Novo Nordisk stock fell in pre-market trade after predicting weaker sales growth for 2026 due to high competition and price pressure. The CEO said the share price might drop before it goes back up. Investors are waiting for a decision from US regulators on a stronger version of their weight-loss drug Wegovy, expected early this year.